雌激素受体(ER)阳性乳腺癌患者的临床治疗选择 乳腺癌可根据雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER2)的表达情况分为4种分子亚型:①管腔A型(ER+、PR+、HER2-),②管腔B型(ER+、PR+、HER2+),③三阴型(ER-、PR-、HER2-),④HER2过表达型(ER-、PR-、HER2+)。其中ER阳性乳腺癌约占所有...
在HER3靶点方面,HER3-DXd在HER2阴性乳腺癌也有应用前景,例如此次ESMO-BC报道的ICARUS-BREAST01研究显示,3个月HER3-DXd治疗HR+/HER2-或HER2低表达患者,56例患者中,有16例(28.6%)PR和30例(53.6%)SD[11],既往1/2期U31402-A-J101研究则显示治疗HER2+、HR+/HER2-、TNBC的ORR分别为43%、30%和23%[12]。 ...
在HER3靶点方面,HER3-DXd在HER2阴性乳腺癌也有应用前景,例如此次ESMO-BC报道的ICARUS-BREAST01研究显示,3个月HER3-DXd治疗HR+/HER2-或HER2低表达患者,56例患者中,有16例(28.6%)PR和30例(53.6%)SD[11],既往1/2期U31402-A-J10...
参考文献 Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. Lancet Oncol 2018. Published ...
For women with HER2-positive breast cancers, the targeted drugtrastuzumab(Herceptin) has been shown to dramatically reduce the risk of the cancer coming back. It‘s standard treatment to give this medication along withchemotherapyafter surgery to people with breast cancer that’s spread to other ar...
crinetherapyinestrogenreceptorfER)一positivebreastcancerpatients.Itisrecommendedf0rthepatientswithbothER andPRpositivetoreceiveadjuvanthormonetherapy.However,itstillisacontroversialissuehownluchefficacv0fadju— rantendocrinetherapyisforER(一)PR(+)tumors.Thisstudywastoinvestigatetheoptionsofadjuvantendocrinethera— ...
Treatment-induced amenorrhea improves prognosis of early, ER/PR-positive breast cancerdoi:10.1016/S1548-5315(11)70081-XMGnantandRGreilandEKubistaSDOSCommunity Oncology
Ruta D. Rao, MD, and Virginia G. Kaklamani, MD, discuss with participants the case of a patient with breast cancer who has received multiple lines of therapy and what the next steps are for her treatment. CASE SUMMARY Initial presentation: A 56-year-old, postmenopausal woman presented ...
ER 和 PR 属于核激素受体家族成员,与配体结合后具有转录因子的作用。在乳腺癌的发生发展中起到重要作用。正常乳腺腔上皮细胞表达 ER 和/或 PR,可作为免疫组化染色自身阳性内对照辅助判读。 乳腺癌的病理报告中常规对 ER、PR 的表达情况进行评价,ER、PR 阳性表达,提示乳腺癌恶性程度较低,患者预后较好,可指导患者...
While RUNX1 expression has not increased with E2 treatment (Supplementary Figure 1E). Therefore, we hypothesized that PAK4 entry into the nucleus influences RUNX1 subcellular localization. Our previous studies have shown that nuclear PAK4 promotes ERα positive breast cancer bone metastasis [10]. ...